Bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration: A double blind controlled study

Abstract

Fifty patients with corneal dendritic ulceration were randomly entered into a double blind clinical trial comparing BVDU eyedrops with TFT eyedrops. Of those receiving TFT 100% healed in a mean time of 6.7 days, while 92% of those receiving BVDU healed in a mean time of 8.7 days. There was no statistical difference between the two groups in terms of numbers healed, but BVDU was significantly slower in terms of days to heal. After a mean follow-up period of 7.5 months there has been one recurrence in each group.

Brivudine: A herpes virostatic with rapid antiviral activity and once-daily dosing

“…However, although no serious adverse events were noted with treatments, transient stinging was recorded in five patients on trifluorothymidine and only three on brivudine, and one patient in the trifluorothymidine group developed a punctate epitheliopathy (72). Similar results with the two drugs were also noted in a double-blind trial in 50 patients with corneal dendritic ulcerations (73).…”

Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis

“…Whether débridement reduces consequent HSV stromal keratitis (Maudgal 1979; Wilhelmus 1981b) or enhances corneal opacification (Parlato 1985) remains uncertain. Neither a history of HSV epithelial keratitis (HEDS Group 2001) nor short-term antiviral therapy for dendritic epithelial keratitis (HEDS Group 1997; McGill 1981; Patterson 1963a; Power 1991; Wilhelmus 1981a) alters the risk of recurrent herpetic keratitis. For prevention, chronic antiviral prophylaxis (Jones 1977) and other strategies have been proposed (Kaufman 2002; Luzi 1983).…”

“… 1 Included idoxuridine studies: Altinisik 1987; Blake 1977; Colin 1981; Collum 1980; Kitano 1985; Klauber 1982; Laibson 1977; MacKenzie 1964; Markham 1977; McCulley 1982; Panda 1995; Pavan-Langston 1976; Vannini 1986; Wellings 1972 2 Included vidarabine studies: Blake 1977; Collum 1985; Coster 1976; Coster 1979; Denis 1983; Jackson 1984; Markham 1977; Pavan-Langston 1976; Pavan-Langston 1981; Van Bijsterveld 1980; Yeakley 1981; Young 1982 3 Included trifluridine studies: Behrens-Baumann 1992; Coster 1976; Coster 1979; Hoang-Xuan 1984; Panda 1995; Parlato 1985; Power 1991; Van Bijsterveld 1980; Wellings 1972 (excluding La Lau 1982 because of imprecise assessment) 4 Included acyclovir studies: Altinisik 1987; Carmassi 1993; Colin 1981; Colin 1983; Colin 1984; Colin 1987; Colin 1997a; Colin 1997b; Colin 2007b; Collum 1980; Collum 1985; Collum 1986; Denis 1983; Hoang-Xuan 1984; Huang 2008a; Jackson 1984; Jensen 1982; Kitano 1985; Klauber 1982; McCulley 1982; Panda 1995; Pavan-Langston 1981; Wilhelmus 1981a; Yeakley 1981; Young 1982 (excluding La Lau 1982 because of imprecise assessment) 5 Included brivudine studies: Panda 1995; Power 1991; Van Bijsterveld 1989 6 Included ganciclovir studies: Colin 1997a; Colin 1997b; <...>…”

“… 3 Included trifluridine studies: Behrens-Baumann 1992; Coster 1976; Coster 1979; Hoang-Xuan 1984; Panda 1995; Parlato 1985; Power 1991; Van Bijsterveld 1980; Wellings 1972 (excluding La Lau 1982 because of imprecise assessment) …”

The current management of herpetic eye disease

“…With the advent of new antivirals, particular Acyclovir [1] and BVDU [2], the outlook for herpetic keratitis has improved significantly. One of the manifestations of herpes simplex in the cornea is stromal, or disciform keratitis.…”